EUROMEDICAT

EUROmediCAT: Safety of Medication use in Pregnancy in Relation to Risk of Congenital Malformations

Coordinatore	UNIVERSITY OF ULSTER    more  Organization address address: CROMORE ROAD city: COLERAINE postcode: BT52 1SA contact info Titolo: Dr. Nome: Anne Marie Cognome: Patton Email: send email Telefono: +44 28 70324378 Fax: +44 28 70324905
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	3˙956˙151 €
EC contributo	2˙996˙100 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2010-single-stage
Funding Scheme	CP-FP
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-03-01   -   2015-02-28

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY OF ULSTER  Organization address address: CROMORE ROAD city: COLERAINE postcode: BT52 1SA contact info Titolo: Dr. Nome: Anne Marie Cognome: Patton Email: send email Telefono: +44 28 70324378 Fax: +44 28 70324905	UK (COLERAINE)	coordinator	1˙093˙380.00
2	RIJKSUNIVERSITEIT GRONINGEN  Organization address address: Broerstraat 5 city: GRONINGEN postcode: 9712CP contact info Titolo: Dr. Nome: Jan Cognome: Poutsma Email: send email Telefono: +31 50 3634142 Fax: +31 50 3634500	NL (GRONINGEN)	participant	441˙261.60
3	REGION SYDDANMARK  Organization address address: DAMHAVEN 12 city: VEJLE postcode: 7100 contact info Titolo: Dr. Nome: Ester Cognome: Garne Email: send email Telefono: 4576362200 Fax: 4576363474	DK (VEJLE)	participant	333˙975.75
4	ACADEMISCH ZIEKENHUIS GRONINGEN  Organization address address: Hanzeplein 1 city: GRONINGEN postcode: 9713 GZ contact info Titolo: Mr. Nome: J J Cognome: Breeuwsma Email: send email Telefono: +31 50 3638377 Fax: +31 50 3633041	NL (GRONINGEN)	participant	242˙976.40
5	UNIWERSYTET MEDYCZNY IM KAROLA MARCINKOWSKIEGO W POZNANIU  Organization address address: Ul. Fredry 10 city: POZNAN postcode: 61 701 contact info Titolo: Dr. Nome: Bozena Cognome: Raducha Email: send email Telefono: +48 61 8546036 Fax: +48 61 8546268	PL (POZNAN)	participant	237˙821.25
6	UNIVERSITY OF BATH  Organization address address: CLAVERTON DOWN city: BATH postcode: BA2 7AY contact info Titolo: Ms. Nome: Fiona Cognome: Wallis Email: send email Telefono: +44 1225 386822 Fax: +44 1225 383276	UK (BATH)	participant	232˙000.80
7	SWANSEA UNIVERSITY  Organization address address: SINGLETON PARK city: SWANSEA postcode: SA2 8PP contact info Titolo: Ms. Nome: Julie Cognome: Williams Email: send email Telefono: +44 1792 295824 Fax: +44 1792 513398	UK (SWANSEA)	participant	221˙938.45
8	CONSIGLIO NAZIONALE DELLE RICERCHE  Organization address address: Piazzale Aldo Moro 7 city: ROMA postcode: 185 contact info Titolo: Mr. Nome: Marco Cognome: Borbotti Email: send email Telefono: +39 050 3153720 Fax: +39 050 3153738	IT (ROMA)	participant	155˙823.00
9	QUEEN MARY UNIVERSITY OF LONDON  Organization address address: 327 MILE END ROAD city: LONDON postcode: E1 4NS contact info Titolo: Ms. Nome: Szendeffy Cognome: Tanya Email: send email Telefono: +44 20 7882 7266 Fax: +44 20 7882 7266	UK (LONDON)	participant	36˙922.80

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'A variety of complementary approaches are needed to evaluate safety of medicine use in pregnancy. To evaluate safety in relation to teratogenicity (capacity to cause malformations), population-based congenital anomaly registers, which are already networked across Europe (EUROCAT) with a common database, can provide a cost-effective mechanism which is as yet underexploited. The enormous population coverage of registers when combined gives sufficient statistical power for the identification of associations between specific drugs and specific malformations. This project will develop and test an efficient pharmaco-vigilance system for safety of drugs during pregnancy in relation to teratogenicity by (i) enhancing the information regarding drug exposure in the EUROCAT database, covering a total population of 3 million births 1995-2010, through linkage to electronic databases containing prescription information, and by linkage to chronic disease cohorts (ii) analysing the enhanced EUROCAT database in relation to four drug groups of public health concern - new antiepileptics, insulin analogs, SSRI antidepressants, and antiasthmatics - exposure to all of which is increasing in the pregnant population (iii) interrogating health care databases to monitor the effectiveness of drug safety recommendations and pregnancy prevention programmes through drug utilisation studies, and to provide an exposure profile for pregnant women (iv) conducting a scoping study of the implications for drug safety of growing internet use by pregnant women, in terms of access to safety information about teratogenicity, and access to drugs with teratogenic potential.'

Introduzione (Teaser)

An EU-funded project is building a system to identify medications that could increase teratogenicity, or the risk of congenital anomalies, in pregnant women.